Thoraflex Hybrid
Vascutek, Ltd. · Decision date Sep 8, 2026
What did the FDA approve?
The FDA's decision for P210006/S018 is an approval of a supplement to the existing Thoraflex Hybrid PMA, filed on the Normal 180 Day Track and categorized as a change to design, components, specifications or material. The source statement describes the purpose as approval for new branch configurations of the device, a hybrid stent graft for thoracic aortic lesion treatment with product code QSK.
The identifier ties S018 to original PMA P210006, so this is a modification within that approval rather than a new approval of the whole system. The record does not specify which branches, their dimensions or materials, or any supporting data; the stated purpose of the change is not evidence of safety or clinical effectiveness.
FDA approval order statement
approval for new branch configurations of the Thoraflex Hybrid device
- Regulatory pathway
- PMA supplement
- Supplement type
- Normal 180 Day Track
- Clinical specialty
- Cardiovascular
- Decision date
- Sep 8, 2026
- FDA change category
- Change Design/Components/Specifications/Material
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P210006/S018
- Regulatory pathway
- PMA supplement
- Applicant
- Vascutek, Ltd.
- Product code
- QSK
- Decision code
- APPR
- Decision date
- Sep 8, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Hybrid stent graft, thoracic aortic lesion treatment.
- Applicant
- Vascutek, Ltd.
- Product code
- QSK
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P210006. Subsequent supplements may change the device or its indications.
FDA decision timeline
P210006 · Original PMA
Thoraflex Hybrid
P210006/S018 received
Application receipt date recorded by FDA.
P210006/S018 · FDA decision
Normal 180 Day Track
Timeline entries are records held by MedtechLedger for P210006. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P210006
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Thoraflex HybridP210006 | Vascutek, Ltd. | PMA approval | Apr 19, 2022 | FDA |
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Vascutek, Ltd.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- Newmains Ave., Inchinnan, PA49RR
Sources and methodology
- Original FDA record: P210006/S018
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records